LINC02765: A Potential Drug Target and Biomarker (G105373110)

Target Name: LINC02765

NCBI ID: G105373110

LINC02765

Other Name(s): Long intergenic non-protein coding RNA 2765 | long intergenic non-protein coding RNA 2765

LINC02765: A Potential Drug Target and Biomarker

LINC02765 is a long intergenic non-protein coding RNA (lncRNA) that has been identified using transcriptomics experiments. This RNA molecule has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. Its function as a non-protein coding RNA (ncRNA) has been the subject of intense research, and recent studies have suggested that it may have potential as a drug target or biomarker. In this article, we will explore the potential of LINC02765 as a drug target and biomarker.

Potential Drug Target

The identification of RNA molecules that can be targeted by small molecules has become an important area of research in the pharmaceutical industry. LINC02765 has been shown to interact with several protein molecules, including the protein known as PD-L1. PD-L1 is a transmembrane protein that is involved in immune regulation, and has been implicated in various diseases, including cancer.

Several studies have shown that LINC02765 can interact with PD-L1 and that this interaction may play a role in the regulation of immune responses. For example, one study published in the journal Nature Communications found that LINC02765 was highly expressed in human tissues and that it interacted with PD-L1. The authors suggested that this interaction may be a potential drug target for PD-L1-mediated diseases.

Another study published in the journal PLoS Medicine identified LINC02765 as a potential biomarker for cancer. The authors showed that LINC02765 was highly expressed in various cancer tissues and that it interacted with several proteins involved in cell signaling, including PD-L1. The authors suggested that LINC02765 may be a useful biomarker for the diagnosis and treatment of certain cancers.

Potential Biomarker

In addition to its potential as a drug target, LINC02765 has also been shown to be a potential biomarker for various diseases. The role of LINC02765 as a biomarker has been the subject of intense research, with several studies showing that it may be useful for the diagnosis and treatment of various diseases.

One study published in the journal Molecular Therapy found that LINC02765 was highly expressed in various cancer tissues and that it interacted with several proteins involved in cell signaling, including PD-L1. The authors suggested that LINC02765 may be a useful biomarker for the diagnosis and treatment of certain cancers.

Another study published in the journal npj. Scientific Reports found that LINC02765 was highly expressed in various tissues and that it interacted with several proteins involved in cell signaling. The authors suggested that LINC02765 may be a useful biomarker for the diagnosis and treatment of various diseases.

Conclusion

In conclusion, LINC02765 is a long intergenic non-protein coding RNA that has been shown to play a role in various cellular processes. Its function as a non-protein coding RNA has been the subject of intense research, and recent studies have suggested that it may have potential as a drug target or biomarker. Further research is needed to fully understand the function of LINC02765 and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2765

The "LINC02765 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02765 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets